PB6440 / PhaseBio Pharma, CORXEL - LARVOL DELTA

JX09 SAD/MAD in Healthy Participants (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Ji Xing Pharmaceuticals Australia Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

ENHANCED INHIBITION OF ALDOSTERONE PRODUCTION BY PB6440, A NOVEL AND VERY HIGHLY SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR (ACC-WCC 2023) - "Here we compared PB6440 with baxdrostat and showed PB6440 was significantly more potent and selective than baxdrostat in vitro and in vivo. Baxdrostat had less than 100-fold selectivity for CYP11B2 vs. CYP11B1 compared to more than 300-fold selectivity with PB6440."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease

A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey (ESC 2022) - "PB6440 was well tolerated in the cynomolgus monkey at doses that are much higher than needed for potent aldosterone suppression based on previous studies. At the highest dose level tested (100 mg/kg), which led to a 98% reduction in basal aldosterone levels, no evidence of significant CYP11B1 inhibition was observed. The absence of an increase in plasma potassium in the presence of a plasma sodium decline merits further study."

Clinical • PK/PD data • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Selective and Durable Suppression of Aldosterone Production in Non-Human Primates by a Novel Aldosterone Synthase Inhibitor (ENDO 2019) - "Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*"